Selective, non-peptide corticotropin-releasing factor1
) receptor antagonist (Ki
= 1.7 nM); has no activity at CRF2
receptors. Blocks behavioral seizures in vivo
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
The CRF1 receptor mediates the excitatory actions of corticotropin releasing factor (CRF) in the developing rat brain: in vivo evidence using a novel, selective, non-peptide CRF receptor antagonist.
Baram et al.
Brain Res., 1997;770:89
Design and synthesis of a series of non-peptide high-affinity human corticotropin-releasing factor1 receptor antagonists.
Chen et al.
Recent advances with the CRF1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications.
McCarthy et al.
The citations listed below are publications that use Tocris products. Selected citations for NBI 27914 hydrochloride include:
Showing Results 1 - 7 of 7